Search This Blog

Friday, March 8, 2024

Most Ridiculous Jobs Report In Recent History: Record 1.2 M Immigrant Jobs Added In 1 Month

 Last month we though that the January jobs report was the "most ridiculous in recent history" but, boy, were we wrong because this morning the Biden department of goalseeked propaganda (aka BLS) published the February jobs report, and holy crap was that something else. Even Goebbels would blush. 

What happened? Let's take a closer look.

On the surface, it was (almost) another blockbuster jobs report, certainly one which nobody expected, or rather just one bank out of 76 expected. Starting at the top, the BLS reported that in February the US unexpectedly added 275K jobs, with just one research analyst (from Dai-Ichi Research) expecting a higher number.

Some context: after last month's record 4-sigma beat, today's print was "only" 3 sigma higher than estimates. Needless to say, two multiple sigma beats in a row used to only happen in the USSR... and now in the US, apparently.

Before we go any further, a quick note on what last month we said was "the most ridiculous jobs report in recent history": it appears the BLS read our comments and decided to stop beclowing itself. It did that by slashing last month's ridiculous print by over a third, and revising what was originally reported as a massive 353K beat to just 229K,  a 124K revision, which was the biggest one-month negative revision in two years!

Of course, that does not mean that this month's jobs print won't be revised lower: it will be, and not just that month but every other month until the November election because that's the only tool left in the Biden admin's box: pretend the economic and jobs are strong, then revise them sharply lower the next month, something we pointed out first last summer and which has not failed to disappoint once.

To be fair, not every aspect of the jobs report was stellar (after all, the BLS had to give it some vague credibility). Take the unemployment rate, after flatlining between 3.4% and 3.8% for two years - and thus denying expectations from Sahm's Rule that a recession may have already started - in February the unemployment rate unexpectedly jumped to 3.9%, the highest since February 2022 (with Black unemployment spiking by 0.3% to 5.6%, an indicator which the Biden admin will quickly slam as widespread economic racism or something).

And then there were average hourly earnings, which after surging 0.6% MoM in January (since revised to 0.5%) and spooking markets that wage growth is so hot, the Fed will have no choice but to delay cuts, in February the number tumbled to just 0.1%, the lowest in two years...

... for one simple reason: last month's average wage surge had nothing to do with actual wages, and everything to do with the BLS estimate of hours worked (which is the denominator in the average wage calculation) which last month tumbled to just 34.1 (we were led to believe) the lowest since the covid pandemic...

... but has since been revised higher while the February print rose even more, to 34.3, hence why the latest average wage data was once again a product not of wages going up, but of how long Americans worked in any weekly period, in this case higher from 34.1 to 34.3, an increase which has a major impact on the average calculation.

While the above data points were examples of some latent weakness in the latest report, perhaps meant to give it a sheen of veracity, it was everything else in the report that was a problem starting with the BLS's latest choice of seasonal adjustments (after last month's wholesale revision), which have gone from merely laughable to full clownshow, as the following comparison between the monthly change in BLS and ADP payrolls shows. The trend is clear: the Biden admin numbers are now clearly rising even as the impartial ADP (which directly logs employment numbers at the company level and is far more accurate), shows an accelerating slowdown.

But it's more than just the Biden admin hanging its "success" on seasonal adjustments: when one digs deeper inside the jobs report, all sorts of ugly things emerge... such as the growing unprecedented divergence between the Establishment (payrolls) survey and much more accurate Household (actual employment) survey. To wit, while in January the BLS claims 275K payrolls were added, the Household survey found that the number of actually employed workers dropped for the third straight month (and 4 in the past 5), this time by 184K (from 161.152K to 160.968K).

This means that while the Payrolls series hits new all time highs every month since December 2020 (when according to the BLS the US had its last month of payrolls losses), the level of Employment has not budged in the past year. Worse, as shown in the chart below, such a gaping divergence has opened between the two series in the past 4 years, that the number of Employed workers would need to soar by 9 million (!) to catch up to what Payrolls claims is the employment situation.

There's more: shifting from a quantitative to a qualitative assessment, reveals just how ugly the composition of "new jobs" has been. Consider this: the BLS reports that in February 2024, the US had 132.9 million full-time jobs and 27.9 million part-time jobs. Well, that's great... until you look back one year and find that in February 2023 the US had 133.2 million full-time jobs, or more than it does one year later! And yes, all the job growth since then has been in part-time jobs, which have increased by 921K since February 2023 (from 27.020 million to 27.941 million).

Here is a summary of the labor composition in the past year: all the new jobs have been part-time jobs!

But wait there's even more, because now that the primary season is over and we enter the heart of election season and political talking points will be thrown around left and right, especially in the context of the immigration crisis created intentionally by the Biden administration which is hoping to import millions of new Democratic voters (maybe the US can hold the presidential election in Honduras or Guatemala, after all it is their citizens that will be illegally casting the key votes in November), what we find is that in February, the number of native-born workers tumbled again, sliding by a massive 560K to just 129.807 million. Add to this the December data, and we get a near-record 2.4 million plunge in native-born workers in just the past 3 months (only the covid crash was worse)!

The offset? A record 1.2 million foreign-born (read immigrants, both legal and illegal but mostly illegalworkers added in February!

Said otherwise, not only has all job creation in the past 6 years has been exclusively for foreign-born workers...

Source: St Louis Fed FRED Native Born and Foreign Born

... but there has been zero job-creation for native born workers since June 2018!

This is a huge issue - especially at a time of an illegal alien flood at the southwest border...

... and is about to become a huge political scandal, because once the inevitable recession finally hits, there will be millions of furious unemployed Americans demanding a more accurate explanation for what happened - i.e., the illegal immigration floodgates that were opened by the Biden admin.

Which is also why Biden's handlers will do everything in their power to insure there is no official recession before November... and why after the election is over, all economic hell will finally break loose. Until then, however, expect the jobs numbers to get even more ridiculous.

https://www.zerohedge.com/economics/inside-most-ridiculous-jobs-report-recent-history-12-million-immigrant-jobs-added-one

Huge Percentage of Job Gains are Related to Taking Care of Immigrants

 2024 is starting where 2023 ended. Job growth is soaring, but employment isn’t. Second, the number of jobs needed to take care of illegal immigration is a huge percentage of the increase in jobs.

Data from the BLS, chart by Mish.

The surge in government jobs and social assistance jobs is soaring to handle the massive influx of immigrants.

Health care jobs are rising for the same reason but also because of demographics. Aging boomers need more assistance.

Blistering Start to 2024

  • Government jobs are 20.63 percent of all job growth in 2024.
  • Social assistance jobs are 9.25 percent of all job growth in 2024.
  • Health care jobs ae 25.93 percent of all job growth in 2024.
  • Government plus social assistance provide 29.88 percent of all job growth in 2024.
  • Government plus social assistance plus health care provides 55.81 percent of all job growth in 2024.

Denver Health at “Critical Point” as 8,000 Migrants Make 20,000 Emergency Visits

To help understand the surge in government and social assistance jobs, please note Denver Health at “Critical Point” as 8,000 Migrants Make 20,000 Emergency Visits

The Denver hospital system is turning away local residents because it is flooded with migrant visits.

Eight-thousand migrants from Central America accounted for approximately 20,000 visits in 2023. Denver Health asked the Federal Emergency Management Agency to provide funds for immigrants’ medical costs. The state and federal governments aren’t reimbursing the hospital, which spent $136 million for patients who didn’t pay.

Q&A on Everything He Can

Q: Everything he can? Like what?
A: Like new back doors.

Texas Showdown

In Texas, the Supreme Court Lets Feds Cut Abbott’s Razor Wire

The swing vote, Justice Amy Coney Barrett, is a Trump nominee. Expect to hear calls of “traitor”. There is one way to decide this issue. Vote out Biden. The ruling does help Trump. Meanwhile, the floodgates are open.

Sanctuary Cities Seek More Money for Migrants, But is Money the Problem?

On December 30, I asked Sanctuary Cities Seek More Money for Migrants, But is Money the Problem?

Who Will Pay for This?

You will, to varying degrees.

Those in sanctuary cities like Denver will bear the brunt whether or not the mayor or governor is in denial.

Divergence Between Jobs and Employment

Another seemingly strong jobs headline today falls apart on closer scrutiny. The massive divergence between jobs and employment continues.

Nonfarm payrolls and employment levels from the BLS, chart by Mish.

Payrolls vs Employment Gains Since March 2023

  • Nonfarm Payrolls: 2,602,000
  • Employment Level: +144,000
  • Full Time Employment: -284,000

For more on the divergence between jobs and employment, please see Jobs Up 275,000 with 52,000 More Government Jobs, Employment Down 184,000


https://mishtalk.com/economics/huge-percentage-of-job-gains-are-related-to-taking-care-of-immigrants/

Associate Of DA Alvin Bragg Arrested For Murder After Severed Head Found In Freezer

 by blueapples on X


Following his release after spending 20 years in prison, Sheldon Johnson pledged to turn his life around following and a beacon of hope for other ex-convicts. By becoming an advocate of criminal justice reform, Johnson was well on his way to fulfill that mission. His work saw him bump elbows with the likes of Manhattan District Attorney Alvin Gragg and even garnered him an appearance on the world's most-watched podcast; The Joe Rogan Experience. Yet in one fell swoop, Johnson shattered his promise to be an example that ex-convicts can turn their lives around when he was arrested for murder after police discovered the decapitated head of one of his victim's in the freeze of his Fifth Avenue apartment.

New York City Police discovered the Dahmeresque crime scene after they were called to 979 Summit Avenue in the Highbridge neighborhood of the Bronx. Officers were responding to a wellness check on the tenant in Apartment 6G of the building after building superintendent Orlando Medina called 911. Medina told NYPD that he received a distressing call from another tenant around 1 in the morning. "Someone was pleading for their life. She said she heard two gunshots, someone said 'please don't kill me I got family,' something like that and two more gunshots pretty quickly," Medina said.

Despite receiving the call in the early hours of March 5th, Medina hadn't called the NYPD until 8:25 pm that evening. Police subsequently identified Johnson after reviewing surveillance footage from the building. Footage showed Johnson in the building on separate occasions on the morning of the murder. He was seen entering the building wearing a yellow hoodie, sunglasses, and grown coat while carrying a mop and bag of cleaning supplies. Johnson was also carrying a large blue plastic bin that was brought into the apartment which he never brought out. Building superintendent Medina stated he saw the suspect leave driving the victim's stolen Audi before returning in an Uber later that evening.

Subsequent surveillance footage saw Johnson return to the scene of the crime but this time he was wearing a blonde wig as a disguise. Witnesses corroborated the surveillance footage, adding they saw the suspect coming and going into the apartment with cleaning supplies before police had responded to the call for a wellness check.

The victim, identified as 44 year-old Colin Small, had previously served time in Sing Sing prison concurrent to Johnson's own prison sentence. While NYPD made no remarks about any motive behind the murder, speculation surrounding the gruesome case is that the two had become enemies during their time together in prison at Sing Sing. After identifying Johnson as the suspect, police obtained a search warrant for his Harlem apartment on Fifth Avenue. There, NYPD found the remaining body part's missing from the scene of the crime in Johnson's freezer; namely Small's severed legs and decapitated head. Following his arrest Johnson was charged with murder, manslaughter and criminal possession of a weapon.

Despite the ghastly crime Johnson was caught committed red handed, his supporters flocked to court to attend his arraignment. Among his supporters was Lori Zeno, the executive director of his employer the Queens Defenders. One supporter in attendance was adorned in a jacket that read "specializing in wrongful conviction arrests", alluding to the work Johnson did as a victim's rights advocate which saw him rub elbows with some of the most high profile members of NYC's criminal justice system, like DA Alvin Bragg. That notoriety even led to Johnson appearing on the Joe Rogan Experience just one month before his arrest to talk about how he turned his life around.

Though Johnson was held without bail, the fact that people so fervently came to his side following his arrest shows the disingenuousness of their claims that they are advocates for victim's rights given that their callous disregard of the life of Johnson's victim. Instead, Johnson's self-proclaimed mission is very much analogous to the platform of his associate Alvin Bragg. Each exploited the moral imperative of the cause they supposedly fought for in order to achieve political gain instead of effectuating real change. If Johnson's example proves anything, it's that the likes of him calling for criminal justice reform only seek to reshape the system so that it is works for their benefit.

https://www.zerohedge.com/political/associate-da-alvin-bragg-arrested-murder-after-severed-head-found-freezer

Fresenius Kabi’s Biosimilar for Actemra Gets FDA Approval

 Another biosimilar approval from the FDA was handed down Thursday, as the regulator approved Fresenius Kabi’s Tyenne biosimilar for Genentech’s Acterma (tocilizumab).

According to Fresenius Kabi, Tyenne is the first biosimilar to Acterma which has both IV and subcutaneous formulations approved by the FDA. However, as part of a patent settlement with Genentech, the German pharma has a license to market its biosimilar products in the U.S., which will start on confidential license dates.

The biosimilar is now approved to treat inflammatory and immune diseases such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis.

“The FDA’s approval of our tocilizumab biosimilar is a breakthrough in bringing high-quality, affordable, and accessible autoimmune treatment options to patients and healthcare providers,” Michael Schönhofen, Fresenius Kabi president of biopharma, said in a statement. “We are expanding our biosimilars portfolio for immunology and oncology-related diseases, and we are committed to improving the quality of patients’ lives and lightening the burden on healthcare systems around the world.”

The Tyenne biosimilar has already been launched in 10 countries but Fresenius Kabi plans to launch it in additional  nations this year and in 2025. Acterma pulled in over CHF 1.2 billion ($1.39 billion) in sales in the U.S. in fiscal year 2023 and CHF 2.6 billion ($2.9 billion) in global sales.

“Tyenne met the rigorous FDA requirements for biosimilarity and is another treatment option for patients and their healthcare providers,” Fabrice Romanet, senior vice president of innovation and development at Fresenius Kabi Biopharma, said in a statement.

Tyenne is the third FDA-approved biosimilar for Fresenius Kabi as Stimufend, a Neulastat biosimilar, was approved in February 2023 and the Humira biosimilar Idacio was approved in July 2023.

The Tyenne approval comes as the FDA gave its approval to two of Sandoz’s biosimilars this week. The regulator approved Sandoz’s Jubbonti, which will go up against Amgen’s Prolia in treating osteoporotic men and postmenopausal women at risk of fracture. The other approved biosimilar is Wyost, similar to Amgen’s Xgeva, which is intended to prevent skeletal-related events in patients with multiple myeloma and solid tumors with bone metastases.

https://www.biospace.com/article/fresenius-kabi-s-biosimilar-for-actemra-gets-fda-approval/

Bristol Wins FDA Approval for Opdivo in First-line Bladder Cancer

 Bristol Myers Squibb has won FDA approval for an Opdivo (nivolumab)-based combination in the most common type of bladder cancer, the company reported on Thursday.

The approval covers the use of the checkpoint inhibitor Opdivo in combination with the chemotherapy drugs cisplatin and gemcitabine in the first-line treatment of adults with unresectable or metastatic urothelial carcinoma. In a Phase III trial, patients who received the combination—followed by Opdivo as a monotherapy—lived longer than their peers who received cisplatin and gemcitabine.

Median overall survival (OS) was 21.7 months in the Opdivo cohort, compared to 18.9 months in the control arm. The improvement in OS, coupled to the progression-free survival and safety data, led the FDA to approve the Opdivo combination.

BMS called the Opdivo regimen “the first concurrent immunotherapy-chemotherapy combination approved for this patient population in the U.S.” However, the company will face competition in the bladder cancer space.

Chemotherapy has historically been the go-to first-line treatment for unresectable or metastatic bladder cancer. Pfizer won FDA approval for its checkpoint inhibitor Bavencio (avelumab) as an adjuvant therapy in patients who have undergone chemotherapy in 2020. The big change came in December 2023, when the FDA approved Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab).

The FDA approved Astellas Pharma and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate (ADC), in combination with Merck’s checkpoint inhibitor after seeing Phase III data. In the study, the median OS in the Padcev-Keytruda cohort was 31.5 months, almost twice as long as the 16.1-month median survival in patients who received platinum-based chemotherapy.

Speaking at Pfizer’s Oncology Innovation Day last month, Thomas Powles, professor of urology cancer at the University of London, called the results “by far the most impressive data we've ever seen in urothelial cancer.” The 53% reduction in risk of death is “unprecedented,” Powles said. He expects the data to drive a switch from chemotherapy to the Padcev-Keytruda combination.

While cross-trial comparisons can be misleading, median OS in the Opdivo study was almost 10 months shorter than in the Padcev trial. Some patients are ineligible for cisplatin, making them likely candidates for Padcev. The Phase III study of the ADC enrolled cisplatin-eligible and ineligible patients, positioning Astellas and Pfizer to compete with BMS for people who can take the chemotherapy drug.

Guru Sonpavde, medical director of genitourinary oncology at the AdventHealth Cancer Institute, said the Opdivo data suggest the checkpoint inhibitor “has the potential to change how metastatic or unresectable UC is treated for certain patients” in a statement in BMS’ announcement about the approval.

https://www.biospace.com/article/bms-wins-fda-approval-for-opdivo-in-first-line-bladder-cancer/

NJ Federal Judge Skeptical of Pharma’s Challenge to IRA Drug Price Negotiations

 A New Jersey federal judge on Thursday did not appear to be swayed by arguments from four pharmaceutical companies claiming that the Inflation Reduction Act’s Drug Price Negotiation Program violates their constitutional rights.

Judge Zahid Quraishi was particularly doubtful about the companies’ position that the negotiation program amounted to an unconstitutional taking of their property, according to Law360. Meanwhile, Endpoints News reported that the judge also seemed unconvinced that the negotiations were not voluntary.

Thursday’s hearing was unusual. The court last week agreed to let four pharmaceutical companies—Bristol Myers Squibb, J&J’s Janssen, Novartis and Novo Nordisk—present their oral arguments against the Inflation Reduction Act (IRA) Drug Price Negotiation Program in one prolonged session.

The Thursday morning session included arguments from BMS, Janssen and Novartis, each of which contended that the IRA negotiation program constituted an unlawful taking of the companies’ property in violation of the Fifth Amendment. During the session, the companies also laid out arguments countering the voluntary nature of the program.

After a brief break, Novo and Novartis raised issues unique to their respective cases, such as Novo’s Separation of Powers and Due Process claims against the Medicare drug price negotiations. The afternoon session also heard First Amendment arguments against the IRA program.

Merith Basey, executive director of patient advocacy group Patients For Affordable Drugs in a statement said that the companies’ lawsuits against the drug negotiation program “would not only jeopardize access to vital medications for millions of Americans, but also squander the opportunity for close to $100 billion in savings for taxpayers.”

Thursday’s hearing comes after a Delaware court last week ruled against AstraZeneca, dismissing its due process claims against the IRA’s Drug Price Negotiation Program. U.S. District Judge Colm Connolly wrote in his decision that the pharma had “no legitimate claim of entitlement to sell its drugs to the Government at any price other than what the Government is willing to pay.”

AstraZeneca filed its legal complaint against the IRA program in August 2023 and sought summary judgement in the case a month later. While most lawsuits have focused on constitutional arguments, AstraZeneca took a different route and instead zeroed in on the logistics of its implementation.

There have been many legal challenges to the IRA’s Drug Price Negotiation Program, but none have been successful so far. Last month, a federal district judge in Texas dismissed the lawsuit from industry lobby group Pharmaceutical Research and Manufacturers of America on the grounds of wrong venue.

In October 2023, another federal judge denied the U.S. Chamber of Commerce’s motion for a preliminary injunction against the program, pointing out that the plaintiffs neither had a strong chance of succeeding nor evidence of irreparable harm.

https://www.biospace.com/article/nj-federal-judge-skeptical-of-pharma-s-challenge-to-ira-drug-price-negotiation-program-/